CY1115400T1 - Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων - Google Patents

Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων

Info

Publication number
CY1115400T1
CY1115400T1 CY20141100435T CY141100435T CY1115400T1 CY 1115400 T1 CY1115400 T1 CY 1115400T1 CY 20141100435 T CY20141100435 T CY 20141100435T CY 141100435 T CY141100435 T CY 141100435T CY 1115400 T1 CY1115400 T1 CY 1115400T1
Authority
CY
Cyprus
Prior art keywords
compounds
disorders
producers
pyrazine
suspensions
Prior art date
Application number
CY20141100435T
Other languages
English (en)
Inventor
Jensen Annika Jenmalm
Fredrik Lehmann
Björn M Nilsson
Erik Nordling
Vendela Parrow
Original Assignee
Akinion Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akinion Pharmaceuticals Ab filed Critical Akinion Pharmaceuticals Ab
Publication of CY1115400T1 publication Critical patent/CY1115400T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις του γενικού τύπου (I) όπου τα R1, R2 και R3 είναι όπως ορίζονται εδώ, οι οποίες μπορούν να δρουν ως αναστολείς πρωτεϊνικών κινασών, ειδικότερα της κινάσης 3 της τυροσίνης τύπου Fms (FLT3). Η εφεύρεση αναφέρεται επίσης στη χρησιμοποίηση των ενώσεων σε θεραπεία, σε φαρμακευτικές συνθέσεις περιέχουσες τις ενώσεις και στη χρησιμοποίηση των ενώσεων για την παρασκευή ενός φαρμάκου για την προφύλαξη από και θεραπευτική αγωγή αιματολογικών κακοηθειών, όπως AML, MLL, T-ALL, B-ALL και CMML, μυελοϋπερπλαστικών διαταραχών, άλλων υπερπλαστικών διαταραχών όπως καρκίνος, αυτοάνοσων διαταραχών και δερματικών διαταραχών όπως ψωρίαση και ατοπική δερματίτιδα.
CY20141100435T 2008-02-01 2014-06-17 Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων CY1115400T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0800250 2008-02-01
US12303908P 2008-04-04 2008-04-04
SE0801185 2008-05-21
EP09706385.3A EP2252597B1 (en) 2008-02-01 2009-01-28 Pyrazine derivatives and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1115400T1 true CY1115400T1 (el) 2017-01-04

Family

ID=40527384

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100435T CY1115400T1 (el) 2008-02-01 2014-06-17 Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων

Country Status (19)

Country Link
US (2) US8436171B2 (el)
EP (2) EP2671876A3 (el)
JP (2) JP5562256B2 (el)
KR (1) KR101599082B1 (el)
CN (1) CN101970418B (el)
AU (1) AU2009209633C1 (el)
BR (1) BRPI0907453A2 (el)
CA (1) CA2713553A1 (el)
CY (1) CY1115400T1 (el)
DK (1) DK2252597T3 (el)
ES (1) ES2459297T3 (el)
HK (1) HK1149268A1 (el)
HR (1) HRP20140547T1 (el)
MX (1) MX2010007973A (el)
PL (1) PL2252597T3 (el)
PT (1) PT2252597E (el)
RU (1) RU2493152C2 (el)
SI (1) SI2252597T1 (el)
WO (1) WO2009095399A2 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2252597T3 (pl) * 2008-02-01 2014-09-30 Akinion Pharmaceuticals Ab Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
WO2013089636A1 (en) * 2011-12-15 2013-06-20 Akinion Pharmaceuticals Ab Processes for manufacturing of a kinase inhibitor
KR20140136436A (ko) * 2012-03-14 2014-11-28 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 백혈병을 치료하기 위한 화합물과 방법
MX358311B (es) * 2012-04-17 2018-08-14 Fujifilm Corp Compuesto heterociclico que contiene nitrogeno o sal del mismo.
US20130310387A1 (en) * 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
RU2641106C2 (ru) 2013-10-16 2018-01-16 Фуджифилм Корпорэйшн Соль азотсодержащего гетероциклического соединения или ее кристаллическая форма, фармацевтическая композиция и ингибитор flt3
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
EP3195866B1 (en) 2014-08-22 2020-11-18 FUJIFILM Corporation Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
CN105985322A (zh) * 2015-03-03 2016-10-05 苏州翔实医药发展有限公司 氨基吡嗪化合物及其用途
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US20200171022A1 (en) 2017-05-17 2020-06-04 Inserm (Institut National De La Santé Et Da La Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
EP3654978A4 (en) 2017-07-18 2021-03-31 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSIN ANTAGONISTS
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
CN110483366B (zh) * 2018-05-14 2022-09-16 中国医学科学院药物研究所 吲哚类化合物及其制备方法、药物组合物和用途
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2022517418A (ja) * 2019-01-18 2022-03-08 ニューベイション・バイオ・インコーポレイテッド アデノシンアンタゴニストとしてのヘテロ環式化合物
MX2021008650A (es) * 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112574192B (zh) * 2020-12-24 2021-10-01 烟台大学 氨基酸衍生联噻唑-色胺类抗癌化合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (el) * 1992-04-03 1994-06-21 Ciba Geigy Ag
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
CA2486183C (en) * 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US7390907B2 (en) * 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20080194574A1 (en) 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
CA2561831A1 (en) * 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
ATE517868T1 (de) * 2006-08-16 2011-08-15 Boehringer Ingelheim Int Pyrazinverbindungen, ihre verwendung und herstellungsverfahren
PT2848610T (pt) 2006-11-15 2017-11-14 Ym Biosciences Australia Pty Inibidores da atividade de quinases
PL2252597T3 (pl) * 2008-02-01 2014-09-30 Akinion Pharmaceuticals Ab Pochodne pirazyny i ich zastosowanie jako inhibitorów kinaz białkowych

Also Published As

Publication number Publication date
US8436171B2 (en) 2013-05-07
EP2252597B1 (en) 2014-03-19
RU2010136653A (ru) 2012-03-10
PL2252597T3 (pl) 2014-09-30
JP2011510948A (ja) 2011-04-07
BRPI0907453A2 (pt) 2015-07-14
KR20100116599A (ko) 2010-11-01
SI2252597T1 (sl) 2014-07-31
AU2009209633C1 (en) 2014-01-23
HRP20140547T1 (hr) 2014-07-18
DK2252597T3 (da) 2014-04-28
AU2009209633A1 (en) 2009-08-06
EP2671876A2 (en) 2013-12-11
MX2010007973A (es) 2010-11-09
ES2459297T3 (es) 2014-05-08
WO2009095399A2 (en) 2009-08-06
RU2493152C2 (ru) 2013-09-20
CA2713553A1 (en) 2009-08-06
HK1149268A1 (en) 2011-09-30
PT2252597E (pt) 2014-04-30
US20110098310A1 (en) 2011-04-28
CN101970418A (zh) 2011-02-09
CN101970418B (zh) 2013-07-03
JP5562256B2 (ja) 2014-07-30
KR101599082B1 (ko) 2016-03-02
JP2014148522A (ja) 2014-08-21
AU2009209633B2 (en) 2013-07-18
WO2009095399A3 (en) 2009-10-01
EP2252597A2 (en) 2010-11-24
EP2671876A3 (en) 2014-02-05
US20130203774A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
CY1115400T1 (el) Παραγωγα πυραζινης και χρησιμοποιηση τους ως αναστολεις πρωτεϊνικων κινασων
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1118498T1 (el) Παραγωγα πυριδαζινονης
CY1120260T1 (el) Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk
CY1122611T1 (el) Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
HUS2100028I1 (hu) ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
CY1120826T1 (el) Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης
CY1118717T1 (el) Αναστολεις c-fms κινασης
CY1113665T1 (el) Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
CY1112142T1 (el) Κυκλοπεντα [d] πυριμιδινες ως αναστολεις της κινασης πρωτεϊνης του ακτ
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
HN2010002491A (es) Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina
UA94622C2 (en) Kinase innhibitor
CY1115826T1 (el) Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CL2011000777A1 (es) Compuestos derivados de imidazopiridazina, inhibidor de proteína quinasa; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, psoriasis, artritis reumatoide, angiogenesis, entre otras.
EA201201289A1 (ru) Морфолинилхиназолины
NZ629807A (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
CY1111556T1 (el) Παραγωγα 2-βενζυλοπυριδαζινονης ως αναστολεις μετ-κινασης